Novocure (NVCR) Q3 2026 earnings review
Novocure raises its outlook, but pancreatic cancer prescriptions drop
Novocure, the maker of wearable electric-field devices for cancer, cut its losses while its newest launch lost momentum. Revenue rose 16% from a year ago, or 13% by our math without one-time insurance claim collections, above what the company's own plan pointed to. Chief Executive Frank Leonard raised the full-year outlook again, though by our math the new plan has revenue growth slowing to 8% in the fourth quarter.
| Revenue, excluding one-time claims benefits | +13.0% reported revenue: $193.4M (+15.7% from a year ago) |
|---|---|
| Active patients on therapy | 5,260 +19.1% from a year ago |
| Adjusted EBITDA (profit excluding stock pay and one-offs) | $15.7M -$3.0M a year ago |
| Full-year revenue outlook | Raised $22M middle of the range: 12.8% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the cost improvements held up without last quarter's one-time tariff refund, and Japan reimbursement lifted lung cancer device sales. One caution: the pancreatic cancer launch stumbled, with active patients slipping to 276 and new prescriptions falling 43% from last quarter.
The question now is whether the pancreatic cancer device is hitting an early ceiling or just a pause after its initial wave of prescriptions. Either doctors are hesitating before insurance coverage arrives, or early patients are stopping treatment faster than new ones start. Fourth-quarter prescription counts and Japan's rollout will tell.
🐂 Bull Case
Lower Overhead and Device Costs Narrow the Loss
Novocure makes wearable devices that use electric fields to slow cancer growth, and Chief Executive Frank Leonard wants to "continue to build on the strong progress we have made on our path to profitability". Last quarter's profit benefited from a one-time $4.9 million tariff refund, which raised doubts about whether the improvement would last.
This quarter proved the cost gains are holding without tariff refunds. Gross margin reached 77%, up 3.7 percentage points from a year ago, on "improved array utilization and manufacturing efficiencies". Operating loss shrank from $36.0 million to $6.2 million because the company cut overhead and
- Sales and marketing costs: 27.6% of revenue, down 7.5 percentage points from a year ago
- General and administrative overhead: 22.6% of revenue, down 4.9 percentage points
- Research and development spend: 30.0% of revenue, down 2.3 percentage points
- Adjusted EBITDA (profit before interest, tax, depreciation and stock pay): $15.7 million, up from $10.8 million last quarter
What to watch: fourth-quarter gross margin against the company's mid-to-high 70s target. Holding 77% while adding unreimbursed pancreatic cancer patients would show manufacturing savings can offset launch costs.
Japan Lifts Lung Cancer Device Sales
Optune Lua is Novocure's wearable device for lung cancer and mesothelioma. Early sales in the United States and Germany were slow, so the company relied on Japan after winning national health insurance coverage there in March 2026.
That bet is working, as Optune Lua revenue rose to $8.2 million from $5.4 million last quarter. Japan generated $4.1 million of that total and grew to 110 active patients, up from 64 three months ago. By contrast, active patients in the United States slipped from 99 to 97, showing that older markets remain stuck while Japan carries the product.
What to watch: Japanese active patients on Optune Lua in the fourth quarter. Continued additions at this pace would confirm hospital contracting is no longer a bottleneck.
Brain Cancer Device Keeps Adding Patients
Optune Gio, the company's main device for treating glioblastoma brain tumors, still brings in over 90% of total sales. Active patients using the device rose 11% from a year ago to 4,729, with growth in Germany, Japan and the United States.
By our math, Optune Gio revenue outside China grew 12% from a year ago to $177.0 million. Even after stripping out $4.4 million of "one-time benefits in the U.S. and Germany related to increases in claims approval rates", the brain cancer business grew faster than the mid-to-high single-digit pace assumed in the full-year plan.
What to watch: fourth-quarter FDA decision on using the therapy for brain tumors that spread from lung cancer. Approval would open a new group of brain cancer patients in 2027.
🐻 Bear Case
Pancreatic Cancer Patient Count Stopped Growing
Leonard said third-quarter growth came from Optune Gio and new launches, "resulting in a record number of active patients on our therapies". That framing hides a stall in Optune Pax, the pancreatic cancer device launched in the United States in February 2026 and the centerpiece of the company's expansion plan.
Active patients on Optune Pax fell from 285 in June to 276 in September, as U.S. patients dropped by 19 and Germany added 10. New prescriptions fell 43% from last quarter, dropping from 418 to 238. Because insurers take up to two years to establish broad coverage, Novocure records revenue only when cash arrives: Optune Pax brought in $3.7 million, or about $4,400 per patient a month by our math, less than half the company average.
What to watch: fourth-quarter Optune Pax prescriptions and active patients. Another drop would show that doctors are not writing repeat prescriptions after their first patients finish treatment.
Third Straight Outlook Raise Still Points to a Slowdown
Novocure beat what its prior outlook implied for the third quarter and raised its full-year targets for a third time. That proves the old plan was cautious, but the updated plan still points to a weaker fourth quarter and leaves the company losing money on a standard accounting basis.
- Implied fourth-quarter revenue: $188.5 million at the middle of the range by our math, down 2.5% from the third quarter
- Implied fourth-quarter Adjusted EBITDA: $2.8 million by our math, down from $15.7 million in the third quarter
- Third-quarter GAAP net loss: $10.4 million, driven by $17.5 million in employee stock pay
What to watch: full-year 2027 targets when fourth-quarter results arrive. They will show whether the fourth-quarter dip is just caution or the cost of funding clinical trials.
Risks this quarter didn't answer
Four standing concerns received no new data in the third-quarter press release because full operational details wait for the conference call or quarterly filing.
- Pancreatic cancer prescribing breadth: the release omitted certified prescriber counts and repeat-prescribing rates needed to explain the drop in Optune Pax prescriptions.
- LUNAR-2 trial savings: no update on regulator agreement to shrink the lung cancer trial and save $90 million, while research spending rose 8% from a year ago.
- Brain cancer trial fallback: no update on how to expand the Optune Gio label after the Phase 3 TRIDENT trial failed in June.
- Supplier concentration: no update on adding backup factories in Mexico and Ireland to reduce reliance on single-source suppliers in Israel.
👓 Other Themes
Japan Approval and Drug Combination Trial in Pancreatic Cancer
In October, Japan's health ministry approved Optune Pax for locally advanced pancreatic cancer, opening a second major market after the United States and Germany. Novocure also signed an agreement with Verastem Oncology to test its electric-field therapy alongside Verastem's experimental pill targeting KRAS G12D, a common genetic mutation in pancreatic tumors. The trial tests whether the device can work with new targeted pills rather than lose patients to them.
💲 Other KPIs
Uncollected customer bills rose 27.0% from a year ago to $108.3 million, growing faster than the 15.7% rise in revenue as the company awaits insurance payments. Total cash and short-term investments rose by $13.0 million during the quarter to $473.6 million, including restricted cash.
The Swiss cancer-device maker increased its share count by 4.4% from a year ago through employee stock grants. Meanwhile, $25.0 million of its $196.3 million senior secured loan moved into current liabilities because repayments begin in the third quarter of 2027.
🔮 Guidance
Raised. The middle of the full-year range moved up $22 million, calling for 12.8% growth. By our math, that leaves $188.5 million for the fourth quarter, or 8.1% growth from a year ago after 15.7% in the third quarter. It is the third straight raise, and each was larger than the last: +$10M, +$17.5M, +$22M.
Raised. Management lifted the middle of the profit target by $21.5 million after earning $26.2 million in the first nine months. By our math, the outlook leaves $2.8 million for the fourth quarter, down from $15.7 million this quarter. This is the third raise this year: +$2.5M, +$15M, +$21.5M.
Raised. The middle of the combined target for the two newer devices rose by $7 million. With $22.0 million already recorded in the first nine months, the plan leaves $10.0 million at the middle of the range for the fourth quarter by our math, down from $11.9 million in the third quarter.
Unchanged. The oncology group still plans for roughly 5% to 9% full-year revenue growth from its brain cancer device, even though active patients on the therapy grew 11% from a year ago in the third quarter.
Raised. Novocure lifted its quarterly gross margin assumption from the mid-70s to the mid-to-high 70s after holding a 77% margin in the third quarter on lower device manufacturing costs.
❓ Key Questions
Why did Optune Pax prescriptions fall 43% from last quarter?
New prescriptions for the pancreatic cancer device dropped from 418 in the second quarter to 238, and active patients fell by 9. Investors need to know how many doctors are writing repeat prescriptions and how long patients stay on the device.
What drives the implied fourth-quarter drop in profit?
By our math, the raised full-year outlook leaves $2.8 million of Adjusted EBITDA for the fourth quarter, down from $15.7 million in the third quarter. Management has not explained whether clinical trial timing or launch spending causes that drop.
Have regulators approved the smaller LUNAR-2 lung cancer trial?
Last quarter management planned to cut LUNAR-2 trial spending by $90 million by closing slow sites and amending the trial design. The release gave no update on regulator agreement, while research and clinical spending rose 8% from a year ago.